Skip to main content
Premium Trial:

Request an Annual Quote

More Money, More Science

Researchers in the UK will start to see a bit more cash flowing their way, reports ScienceInsider's Daniel Clery. George Osborne, chancellor of the exchequer, recently announce that his autumn budget would include £200 million for research infrastructure. Though this only goes a short way to restoring science budgets that were severely cut during the UK's round of austerity measures, it does give researchers a little bit of good news, Clery says. Royal Society President Paul Nurse tells Clery that he hopes the announcement is the start of reversing the cuts, and not just a "one off," he says, adding: "We have world class scientists and they need world class places to do their work — you would not keep a Da Vinci in a garden shed."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.